ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,317.59
-0.26%
Dow Jones
39,069.59
0.01%
Gold vs US Dollar
2,353.80
0.71%
Brent Oil
82.845
1.06%
Bitcoin
70,151.23
2.39%
Pepperstone
Advertisement
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Lixte Biotechnology Holdings Inc (LIXT) Share Price

LIXT Lixte Biotechnology Holdings Inc

2.429
0.039 (1.63%)
25 May 2024 - Closed
Delayed by 15 minutes
 Name  Symbol  Market  Type  ISIN  Description 
 Lixte Biotechnology Holdings Inc NASDAQ:LIXT NASDAQ Common Stock  
     Change  % Chg  Cur  Bid  Offer  High  Low  Open  Volume  Chg Time
Upgrade Icon
 		 RN  NRN 
   0.039 1.63 2.429 2.30 4.19 2.485 2.35 2.41 1,468 04:00:17   
 Sector  Turnover  Profit  EPS - Basic  PE ratio  Mkt Cap 
 Pharmaceutical Preparations  -5.09M -2.2616 -1.07 5.47M
 Type  Size  Price  Time  Units 
 13 26 2.40 20:00:00 USD
 
Pre-Market and After-Hours
Recent News
DateTimeSource
HeadlineMore LIXT News
08/05/202414:25GLOBELIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer”
24/04/202420:25APSMixed Shelf Filing Gives Micro Cap Delayed Boost
27/03/202419:35APSBiotech Steals The Show Following Pre-Clinical Data Announcement
27/03/202412:30GLOBENEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES
21/03/202412:30GLOBELIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments
27/02/202421:59EDGAR2Form 8-K - Current report
27/02/202413:30GLOBEProfessor René Bernards to Present New Pre-Clinical Data on LIXTE’s LB-100 at Joint Conference of European and American Associations for Cancer Research
Period
Draw mode
Data Downloads for LIXT

Export historical price information open, high, low, close, volume (OHLCV) to Excel

Intraday price data (2 weeks, 1 minute bars)


Loading Follow Feed...

Latest Lixte Biotechnology Holdings Inc Articles